Where Covetrus Stands With Analysts
Within the last quarter, Covetrus (NASDAQ:CVET) has observed the following analyst ratings:
Benzinga ·
Get all your news in one place.
100's of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100's of premium titles. One news app.
The Latest Breaking News from CVET
CD&R, TPG Take Covetrus Private In $4B Deal
Clayton, Dubilier & Rice (CD&R), a private investment firm, and TPG Capital will acquire animal-health technology and services company Covetrus Inc (NASDAQ:CVET) for $21.00 per share, representing an enterprise value of approximately $4 billion. CD&R and its affiliates currently beneficially own approximately 24% of the company's outstanding shares of common stock. The transaction…
Benzinga ·
Raymond James View Skewed Scenarios On Absent Supportive Bid For This Animal Health Stock
Raymond James downgraded the rating on Covetrus Inc (NASDAQ:CVET) from Outperform to Market Perform and removed the prior $22 price target after the company received a buyout at $21 per share. Though $21 may not ultimately prove to be the final resting place in terms of the offer price. Raymond James believes the proposed purchase…
Benzinga ·
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Coverage From
Benzinga
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Read news from The Economist, FT, and more,
with one subscription
with one subscription
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.
100+ trusted global sources.
